Takeda Pharmaceutical (TAK) Consolidated Net Income (2017 - 2026)

Takeda Pharmaceutical's Consolidated Net Income history runs 10 years deep, the most recent figure standing at -$3.6 billion for Q1 2026.

• On a quarterly basis, Consolidated Net Income fell 384.49% year-over-year to -$3.6 billion in Q1 2026; TTM through Mar 2026 was -$3.2 billion, a 185.37% decrease from a year earlier, with the FY2026 full-year figure at -$1.0 billion, down 242.35% from the prior year.
• Consolidated Net Income slipped to -$3.6 billion in Q1 2026 per TAK's latest filing, from -$3.5 billion in the prior quarter.
• Across five years, Consolidated Net Income topped out at $2.8 billion in Q3 2025 and bottomed at -$3.6 billion in Q1 2026.
• The 5-year median for Consolidated Net Income is $1.2 billion (2024), against an average of $707.5 million.
• Across the five-year window, Consolidated Net Income surged 297.92% in 2023 and slumped 4440.99% in 2024, its largest moves.
• Year by year, Consolidated Net Income stood at $673.6 million in 2022, then tumbled by 96.58% to $23.0 million in 2023, then slumped by 4440.99% to -$998.5 million in 2024, then tumbled by 252.45% to -$3.5 billion in 2025, then fell by 1.68% to -$3.6 billion in 2026.
• Per Business Quant, the three latest TAK Consolidated Net Income figures stand at -$3.6 billion (Q1 2026), -$3.5 billion (Q4 2025), and $2.8 billion (Q3 2025).